Literature DB >> 9621196

Campylobacter jejuni strains from patients with Guillain-Barré syndrome.

B M Allos1, F T Lippy, A Carlsen, R G Washburn, M J Blaser.   

Abstract

Guillain-Barré syndrome (GBS), an acute demyelinating peripheral neuropathy, may be triggered by an acute infectious illness; infection with Campylobacter jejuni is the most frequently reported antecedent event. In Japan, O:19 is the most common serotype among GBS-associated C. jejuni strains. To determine whether serotype O:19 occurs among GBS-associated strains in the United States and Europe, we serotyped seven such strains and found that two (29%) of seven GBS-associated strains from patients in the United States and Germany were serotype O:19. To determine whether GBS-associated strains may be resistant to killing by normal human serum (NHS), we studied the serum susceptibility of 17 GBS- and 27 enteritis-associated strains (including many O:19 and non-O:19 strains) using C. jejuni antibody positive (pool 1) or negative (pool 2) human serum. Using pool 1 serum we found that one (6%) of 18 serotype O:19 strains compared with 11 (42%) of 26 non-O:19 strains were killed; results using pool 2 serum were nearly identical. Finally, 8 O:19 and 8 non-O:19 strains were not significantly different in their ability to bind complement component C3. Serotype O:19 C. jejuni strains were overrepresented among GBS-associated strains in the United States and Germany and were significantly more serum-resistant than non-O:19 strains. The mechanism of this resistance appears unrelated to C3 binding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621196      PMCID: PMC2640125          DOI: 10.3201/eid0402.980213

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  22 in total

1.  Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance.

Authors:  M J Blaser; P F Smith; J E Repine; K A Joiner
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  No association with HLA-DR, -DQ or -DP alleles in Guillain-Barré syndrome.

Authors:  J Hillert; P O Osterman; O Olerup
Journal:  J Neuroimmunol       Date:  1991-01       Impact factor: 3.478

3.  HLA antigens in the Guillain-Barré syndrome.

Authors:  J B Winer; D Briggs; K Welsh; R A Hughes
Journal:  J Neuroimmunol       Date:  1988-04       Impact factor: 3.478

4.  Susceptibility of Helicobacter pylori to the bactericidal activity of human serum.

Authors:  G Gonzalez-Valencia; G I Perez-Perez; R G Washburn; M J Blaser
Journal:  Helicobacter       Date:  1996-03       Impact factor: 5.753

5.  Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains.

Authors:  A J Lastovica; E A Goddard; A C Argent
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

6.  Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile antigenic factors.

Authors:  H Lior; D L Woodward; J A Edgar; L J Laroche; P Gill
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

7.  Pathogenesis of Campylobacter fetus infections: serum resistance associated with high-molecular-weight surface proteins.

Authors:  M J Blaser; P F Smith; J A Hopkins; I Heinzer; J H Bryner; W L Wang
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

8.  Extraintestinal Campylobacter jejuni and Campylobacter coli infections: host factors and strain characteristics.

Authors:  M J Blaser; G P Perez; P F Smith; C Patton; F C Tenover; A J Lastovica; W I Wang
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

9.  A prospective study of acute idiopathic neuropathy. II. Antecedent events.

Authors:  J B Winer; R A Hughes; M J Anderson; D M Jones; H Kangro; R P Watkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

10.  Susceptibility of Campylobacter isolates to the bactericidal activity of human serum.

Authors:  M J Blaser; P F Smith; P F Kohler
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

View more
  14 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

2.  Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.

Authors:  H P Endtz; C W Ang; N van Den Braak; B Duim; A Rigter; L J Price; D L Woodward; F G Rodgers; W M Johnson; J A Wagenaar; B C Jacobs; H A Verbrugh; A van Belkum
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Chemical validation of molecular mimicry: interaction of cholera toxin with Campylobacter lipooligosaccharides.

Authors:  Seigo Usuki; Mohanasundari Pajaniappan; Stuart A Thompson; Robert K Yu
Journal:  Glycoconj J       Date:  2007-01-17       Impact factor: 2.916

4.  Molecular mimicry: sensitization of Lewis rats with Campylobacter jejuni lipopolysaccharides induces formation of antibody toward GD3 ganglioside.

Authors:  Seigo Usuki; Stuart A Thompson; Michael H Rivner; Kyoji Taguchi; Keiko Shibata; Toshio Ariga; Robert K Yu
Journal:  J Neurosci Res       Date:  2006-02-01       Impact factor: 4.164

5.  Antibody responses to Campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients.

Authors:  M A Strid; J Engberg; L B Larsen; K Begtrup; K Mølbak; K A Krogfelt
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

6.  The galE gene of Campylobacter jejuni is involved in lipopolysaccharide synthesis and virulence.

Authors:  B N Fry; S Feng; Y Y Chen; D G Newell; P J Coloe; V Korolik
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Effects of sequential Campylobacter jejuni 81-176 lipooligosaccharide core truncations on biofilm formation, stress survival, and pathogenesis.

Authors:  Mizue Naito; Emilisa Frirdich; Joshua A Fields; Mark Pryjma; Jianjun Li; Andrew Cameron; Michel Gilbert; Stuart A Thompson; Erin C Gaynor
Journal:  J Bacteriol       Date:  2010-02-05       Impact factor: 3.490

8.  Differentiation of Campylobacter jejuni serotype O19 strains from non-O19 strains by PCR.

Authors:  N Misawa; B M Allos; M J Blaser
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

9.  Comparative genomic analysis of Campylobacter jejuni associated with Guillain-Barré and Miller Fisher syndromes: neuropathogenic and enteritis-associated isolates can share high levels of genomic similarity.

Authors:  Eduardo N Taboada; Alex van Belkum; Nobuhiro Yuki; Rey R Acedillo; Peggy Cr Godschalk; Michiaki Koga; Hubert P Endtz; Michel Gilbert; John He Nash
Journal:  BMC Genomics       Date:  2007-10-05       Impact factor: 3.969

10.  Targeting Bacillosamine Biosynthesis in Bacterial Pathogens: Development of Inhibitors to a Bacterial Amino-Sugar Acetyltransferase from Campylobacter jejuni.

Authors:  Joris W De Schutter; James P Morrison; Michael J Morrison; Alessio Ciulli; Barbara Imperiali
Journal:  J Med Chem       Date:  2017-02-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.